72F fusion protein vaccine
72F fusion protein vaccine is a candidate tuberculosis vaccine created by Statens Serum Institut (SSI). The 72F fusion protein is composed of the Rv0125 and Rv1196 proteins derived from Mycobacterium tuberculosis. Phase I clinical trials were completed in 2005 and Phase II trials are awaited.
See also
- Fusion protein
References
- Kaufmann SHE, McMichael AJ (2005). "Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis". Nature Medicine. 11 (4 suppl): S33–S44. doi:10.1038/nm1221. PMID 15812488.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.